Source:http://linkedlifedata.com/resource/pubmed/id/16864701
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2006-7-25
|
pubmed:abstractText |
Necrotizing enterocolitis (NEC) is a potentially fatal illness in premature neonates. Tumor necrosis factor alpha (TNF-alpha) has been shown to play a central role in the inflammatory cascade leading to the development of NEC. Published evidence points to a significant role of pentoxifylline in inhibition of TNF-alpha and in reducing mucosal injury and improving healing in ischemia-reperfusion experiments. Our aim was to investigate the effect of pentoxifylline on the incidence of NEC in a neonatal rat model. Newborn Sprague-Dawley rat pups originating from eight separate litters were delivered by cesarean section at 21.5 d and were formula fed from birth by orogastric gavage. The rat pups were randomized to receive either intraperitoneal pentoxifylline (15 mg/kg/dose) or placebo, given every 8 h beginning at 24 h of age, in a blinded fashion. Experimental NEC was induced by exposure to hypoxia for 60 s followed by cold stress at 4 degrees C for 10 min. The animals were euthanized at development of NEC or at 96 h and intestinal tissue was processed and examined for histologic changes of NEC. The incidence of NEC was significantly lower in the pentoxifylline group [pentoxifylline 5/38 versus placebo 15/36; p = 0.008, odds ratio (OR) = 0.21 95% confidence interval (CI) 0.07-0.67]. Among the pups developing NEC, significantly fewer rat pups treated with pentoxifylline had severe (>or=3) intestinal injury scores [pentoxifylline 1/5 versus placebo 10/15; p = 0.031, OR 0.06, 95% CI 0.01-0.79]. We conclude that intraperitoneal administration of pentoxifylline significantly reduced the incidence and severity of NEC in our experimental animal model.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0031-3998
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
60
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
185-9
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:16864701-Animals,
pubmed-meshheading:16864701-Animals, Newborn,
pubmed-meshheading:16864701-Disease Models, Animal,
pubmed-meshheading:16864701-Enterocolitis, Necrotizing,
pubmed-meshheading:16864701-Free Radical Scavengers,
pubmed-meshheading:16864701-Incidence,
pubmed-meshheading:16864701-Intestines,
pubmed-meshheading:16864701-Pentoxifylline,
pubmed-meshheading:16864701-Premature Birth,
pubmed-meshheading:16864701-Rats,
pubmed-meshheading:16864701-Rats, Sprague-Dawley
|
pubmed:year |
2006
|
pubmed:articleTitle |
Pentoxifylline reduces the incidence and severity of necrotizing enterocolitis in a neonatal rat model.
|
pubmed:affiliation |
Women's and Children's Health Service, Women's and Infants' Research Foundation and The University of Western Australia, Perth, Australia.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|